Syndax Pharmaceuticals (SNDX) Reports Q3 Loss, Tops Revenue Estimates
Portfolio Pulse from
Syndax Pharmaceuticals (SNDX) reported a Q3 loss of $0.98 per share, which was better than the Zacks Consensus Estimate of a $1.13 loss. This is an increase in loss compared to $0.73 per share a year ago.
November 05, 2024 | 11:30 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Syndax Pharmaceuticals reported a Q3 loss of $0.98 per share, better than the expected $1.13 loss, but worse than last year's $0.73 loss.
Syndax Pharmaceuticals' Q3 loss was less than expected, which is a positive surprise for investors, potentially leading to a short-term stock price increase. However, the loss is higher than last year's, which may temper enthusiasm.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100